372 related articles for article (PubMed ID: 33706079)
1. Cardiovascular effects of omega-3 fatty acids: Hope or hype?
Jo SH; Han SH; Kim SH; Eckel RH; Koh KK
Atherosclerosis; 2021 Apr; 322():15-23. PubMed ID: 33706079
[TBL] [Abstract][Full Text] [Related]
2. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
3. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
4. Effect of Eicosapentaenoic Acid/Docosahexaenoic Acid on Coronary High-Intensity Plaques Detected Using Noncontrast T1-weighted Imaging: The AQUAMARINE EPA/DHA Randomized Study.
Nakao K; Noguchi T; Miura H; Asaumi Y; Morita Y; Takeuchi S; Matama H; Sawada K; Doi T; Hosoda H; Nakashima T; Honda S; Fujino M; Yoneda S; Kawakami S; Nagai T; Nishihira K; Kanaya T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Kusano K; Yamamoto H; Omae K; Ogawa H; Yasuda S
J Atheroscler Thromb; 2024 Feb; 31(2):122-134. PubMed ID: 37704431
[TBL] [Abstract][Full Text] [Related]
5. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
6. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
8. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Nicholls SJ; Lincoff AM; Garcia M; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Ridker PM; Ray KK; Katona BG; Himmelmann A; Loss LE; Rensfeldt M; Lundström T; Agrawal R; Menon V; Wolski K; Nissen SE
JAMA; 2020 Dec; 324(22):2268-2280. PubMed ID: 33190147
[TBL] [Abstract][Full Text] [Related]
9. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
10. History and future of omega-3 fatty acids in cardiovascular disease.
Sperling LS; Nelson JR
Curr Med Res Opin; 2016; 32(2):301-11. PubMed ID: 26566071
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki KC; Dicklin MR
Curr Opin Cardiol; 2020 Jul; 35(4):417-422. PubMed ID: 32412960
[TBL] [Abstract][Full Text] [Related]
12. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
13. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
Mosca L; Navar AM; Wenger NK
J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
[TBL] [Abstract][Full Text] [Related]
14. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids.
Kris-Etherton PM; Richter CK; Bowen KJ; Skulas-Ray AC; Jackson KH; Petersen KS; Harris WS
Methodist Debakey Cardiovasc J; 2019; 15(3):171-178. PubMed ID: 31687095
[TBL] [Abstract][Full Text] [Related]
15. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
16. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Preston Mason R
Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
[TBL] [Abstract][Full Text] [Related]
17. Do patients benefit from omega-3 fatty acids?
Sherratt SCR; Mason RP; Libby P; Steg PG; Bhatt DL
Cardiovasc Res; 2024 Feb; 119(18):2884-2901. PubMed ID: 38252923
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists.
Patel D; Busch R
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):524-532. PubMed ID: 34191622
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
[TBL] [Abstract][Full Text] [Related]
20. Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis.
Quispe R; Alfaddagh A; Kazzi B; Zghyer F; Marvel FA; Blumenthal RS; Sharma G; Martin SS
Curr Atheroscler Rep; 2022 Jul; 24(7):571-581. PubMed ID: 35499805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
